← Eichor
Condition: Her2 Gastric Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Her2 Gastric Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
EARLY_Phase 1 · 1 location(s) · Vanderbilt-Ingram Cancer Center · NCT06828588A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG
Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT06774222Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-posit
Phase N/A · 36 location(s) · Daiichi Sankyo · NCT06846996HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
Phase 1 · 1 location(s) · Jiangsu Hansoh Pharmaceutical Co., Ltd. · NCT06769425A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Canc
Phase 1 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06500052Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
Phase 1/Phase 2 · 11 location(s) · Vironexis Biotherapeutics Inc. · NCT07192432DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinom
Phase 2/Phase 3 · 12 location(s) · RemeGen Co., Ltd. · NCT06221748At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 · 2 location(s) · Mayo Clinic · NCT05969860Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
Phase 2 · 2 location(s) · Massachusetts General Hospital · NCT07070466M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1
Phase 3 · 1 location(s) · FutureGen Biopharmaceutical (Beijing) Co., Ltd · NCT06177041Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
Phase 1 · 3 location(s) · Fox Chase Cancer Center · NCT05274048Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens
Phase 1/Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT06572319BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer
Phase 1 · 1 location(s) · Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. · NCT06773312Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease
Phase 2 · 1 location(s) · Gruppo Oncologico del Nord-Ovest · NCT06253650T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Phase 1/Phase 2 · 1 location(s) · Yonsei University · NCT05894824Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
Phase 2 · 11 location(s) · RemeGen Co., Ltd. · NCT06155383Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523529Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative G
Phase 3 · 10 location(s) · Sun Yat-sen University · NCT05918094Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta
Phase 3 · 286 location(s) · AstraZeneca · NCT07431281Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer
Phase 2 · 1 location(s) · Fudan University · NCT05975749First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
Phase 2 · 20 location(s) · Qilu Hospital of Shandong University · NCT06730373Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric
Phase 1/Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT07334431Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients Wi
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06364410A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab Wi
Phase 3 · 1 location(s) · RemeGen Co., Ltd. · NCT07315750Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Te
Phase 1/Phase 2 · 105 location(s) · Boehringer Ingelheim · NCT06324357Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer
Phase 2 · 1 location(s) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT05671822mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Neg
Phase 3 · 794 location(s) · Alliance for Clinical Trials in Oncology · NCT05677490A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
Phase 2 · 10 location(s) · Memorial Sloan Kettering Cancer Center · NCT06123338Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing So
Phase 1 · 7 location(s) · Myeloid Therapeutics · NCT07334119A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Phase 1 · 158 location(s) · Seagen, a wholly owned subsidiary of Pfizer · NCT04389632
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.